Abstract
Early clinical response (ECR) is a new endpoint to determine whether a drug should be approved for community-acquired bacterial pneumonia in the United States. The Omadacycline for Pneumonia Treatment In the Community (OPTIC) phase III study demonstrated noninferiority of omadacycline to moxifloxacin using this endpoint. This study describes the performance of the ECR endpoint and clinical stability relative to a posttreatment evaluation (PTE) of clinical success. ECR was defined as symptom improvement 72-120 hours after the first dose of study drug (ECR window), no use of rescue antibiotics, and patient survival. Clinical success at PTE was an investigator assessment of success. Clinical stability was defined based on vital sign stabilization, described in the American Thoracic Society and Infectious Diseases Society of America community-acquired pneumonia treatment guidelines. During the ECR window, ECR was achieved in 81.1% and 82.7% of omadacycline and moxifloxacin patients, respectively. Similar numbers of patients achieved clinical stability in each treatment group (omadacycline 74.6%, moxifloxacin 77.6%). The proportion of patients with improved symptoms who were considered clinically stable increased across the ECR wind...Continue Reading
References
Jun 26, 1995·Archives of Internal Medicine·J A RamirezM J Raff
May 26, 1998·JAMA : the Journal of the American Medical Association·E A HalmD E Singer
Jun 13, 2001·American Journal of Respiratory and Critical Care Medicine·M S NiedermanUNKNOWN American Thoracic Society
Jun 1, 2002·Archives of Internal Medicine·Ethan A HalmAlbert L Siu
Dec 4, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rosario MenéndezUNKNOWN Neumofail Group
Feb 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellUNKNOWN American Thoracic Society
Jun 30, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·George H TalbotUNKNOWN CABP-ABSSSI Project Team
Nov 13, 2012·The European Respiratory Journal·Stefano AlibertiJulio Ramirez
Oct 31, 2013·Journal of the American Association of Nurse Practitioners·Cherese SeversonMeg Fitzhugh
Dec 17, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·George H TalbotUNKNOWN Biomarkers Consortium of the Foundation for the National Institutes of Health CABP-ABSSSI and HABP-VABP Project Teams
Dec 22, 2016·International Journal of Molecular Sciences·Catia CillonizAntoni Torres
Oct 12, 2017·Chest·Brandon H HayesNeil M Vora
Oct 12, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Julio A RamirezUNKNOWN University of Louisville Pneumonia Study Group
Feb 7, 2019·The New England Journal of Medicine·Roman StetsEvan Loh
Citations
Aug 2, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jason C Gallagher
Nov 28, 2019·Clinical Pharmacokinetics·Keith A RodvoldManjunath P Pai
Jun 26, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stephen M BartJohn J Farley
Jun 26, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·George H Talbot
Jan 24, 2020·Drugs·George G ZhanelJames A Karlowsky
Sep 23, 2020·Future Microbiology·Teena ChopraGlenn Tillotson
Jan 24, 2021·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Antoni TorresPaul C McGovern
Mar 9, 2021·ELife·Evdoxia KyriazopoulouEvangelos J Giamarellos-Bourboulis
Jun 1, 2021·Respiratory Medicine·Manjunath P PaiPaul McGovern